Therapeutics for Multiple Sclerosis Symptoms

被引:38
|
作者
Ben-Zacharia, Aliza Bitton [1 ]
机构
[1] Mt Sinai Sch Med, Corinne Goldsmith Dickinson Ctr Multiple Sclerosi, New York, NY USA
来源
MOUNT SINAI JOURNAL OF MEDICINE | 2011年 / 78卷 / 02期
关键词
multiple sclerosis; quality of life; rehabilitation; symptoms management; FEMALE SEXUAL DYSFUNCTION; CONTROLLED-TRIAL; PHARMACOLOGICAL MANAGEMENT; COGNITIVE IMPAIRMENT; DOUBLE-BLIND; DEPRESSION; SPASTICITY; FAMPRIDINE; FATIGUE; PAIN;
D O I
10.1002/msj.20245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Symptoms management in multiple sclerosis is an integral part of its care. Accurate assessment and addressing the different symptoms provides increased quality of life among patients with multiple sclerosis. Multiple sclerosis symptoms may be identified as primary, secondary, or tertiary symptoms. Primary symptoms, such as weakness, sensory loss, and ataxia, are directly related to demyelination and axonal loss. Secondary symptoms, such as urinary tract infections as a result of urinary retention, are a result of the primary symptoms. Tertiary symptoms, such as reactive depression or social isolation, are a result of the social and psychological consequences of the disease. Common multiple sclerosis symptoms include fatigue and weakness; decreased balance, spasticity and gait problems; depression and cognitive issues; bladder, bowel, and sexual deficits; visual and sensory loss; and neuropathic pain. Less-common symptoms include dysarthria and dysphagia, vertigo, and tremors. Rare symptoms in multiple sclerosis include seizures, hearing loss, and paralysis. Symptom management includes nonpharmacological methods, such as rehabilitation and psychosocial support, and pharmacological methods, ie, medications and surgical procedures. The keys to symptom management are awareness, knowledge, and coordination of care. Symptoms have to be recognized and management needs to be individualized. Multiple sclerosis therapeutics include nonpharmacological strategies that consist of lifestyle modifications, rehabilitation, social support, counseling, and pharmacological agents or surgical procedures. The goal is vigilant management to improve quality of life and promote realistic expectations and hope. Mt Sinai J Med 78:176-191, 2011. (C) 2011 Mount Sinai School of Medicine
引用
收藏
页码:176 / 191
页数:16
相关论文
共 50 条
  • [31] Depressive symptoms in multiple sclerosis
    Kano, O.
    Yoshii, Y.
    Cridebring, D.
    Ikeda, K.
    Iwasaki, Y.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2012, 125 (03): : E19 - E19
  • [32] Menopause and Multiple Sclerosis: The Effects of the Perimenopausal Period on Multiple Sclerosis Symptoms
    Sheehan, Julie
    O'Connell, Pauline
    Jose, Josmi
    Tubridy, Niall
    McGuigan, Christopher
    Gaughan, Maria
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 722 - 723
  • [33] Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics
    Collongues, Nicolas
    Patte-Mensah, Christine
    De Seze, Jerome
    Mensah-Nyagan, Ayikoe-Guy
    Derfuss, Tobias
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (06) : 515 - 522
  • [34] Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients
    Hegen, Harald
    Auer, Michael
    Deisenhammer, Florian
    [J]. DRUGS, 2016, 76 (15) : 1421 - 1445
  • [35] Novel Therapeutics for Multiple Sclerosis Designed by Parasitic Worms
    Dixit, Aakanksha
    Tanaka, Akane
    Greer, Judith M.
    Donnelly, Sheila
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
  • [36] Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics
    Ontaneda, Daniel
    Hyland, Megan
    Cohen, Jeffrey A.
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 63, 2012, 63 : 389 - 404
  • [37] The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics
    Camara-Lemarroy, Carlos R.
    Metz, Luanne
    Meddings, Jonathan B.
    Sharkey, Keith A.
    Yong, V. Wee
    [J]. BRAIN, 2018, 141 : 1900 - 1916
  • [38] Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients
    Harald Hegen
    Michael Auer
    Florian Deisenhammer
    [J]. Drugs, 2016, 76 : 1421 - 1445
  • [39] An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis
    Rahiman, Niloufar
    Zamani, Parvin
    Badiee, Ali
    Arabi, Leila
    Alavizadeh, Seyedeh Hoda
    Jaafari, Mahmoud Reza
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2021, 18 (12) : 1795 - 1813
  • [40] Correction to: Gut Microbiome as Potential Therapeutics in Multiple Sclerosis
    Wen Zhu
    Kiersten Dykstra
    Lili Zhang
    Zongqi Xia
    [J]. Current Treatment Options in Neurology, 2021, 23